Seqens Seqens

X

Find the latest Drugs in Development and Pipeline Prospector News of IDBiologics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
IDBiologics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
Nashville, TN
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Results Published demonstrates the ability of ultra-potent monoclonal antibodies to completely neutralize the SARS-CoV-2 virus. These ultra-potent antibodies neutralize the SARS-CoV-2 virus with similar potencies as monoclonal antibodies published in peer-reviewed journals.


Lead Product(s): IDB003

Therapeutic Area: Infections and Infectious Diseases Product Name: IDB003

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

For assessment and future licensing and clinical development, certain monoclonal antibodies discovered in Dr. James Crowe's laboratory at the Vanderbilt Vaccine Center will be shared with IDBiologics.


Lead Product(s): Monoclonal antibody

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Large molecule

Partner/Sponsor/Collaborator: Vanderbilt University Medical Center

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY